Asia-Pacific sovereign rating is expected to remain stable for the foreseeable future as the number of negative outlooks for Asia-Pacific economies remains at a level not seen since the mid-2010, said S&P Global Ratings in a report
According to the report, there were around 15 sovereign ratings with a stable outlook and 5 with negative economic outlook, expect Indonesia which only poses positive outlook. It is worth noting that the recent political developments in advance countries are adding to the challenges that Asia-Pacific sovereigns face.
"Global economic performance is still weighed down by the lacklustre performances of some advanced economies," said S&P Global Rating credit analyst Kim Eng Tan in its report.
"Anti-globalization sentiments are increasing and the risk of protectionist measures is growing. This is a negative development for Asia-Pacific, which has benefited much from global trade and investment flows. The risk may rise further if upcoming elections in Europe produce more surprises," Mr Tan added.
Lastly, we foresee that if anti-trade policies become more likely or if the European Union finds further difficulties in trading in the single market, financial market volatility could return in the near future. And the resulting deterioration in financing conditions for sovereigns in this region could weaken credit metrics even before the trade impact becomes evident.


FxWirePro: Daily Commodity Tracker - 21st March, 2022
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 



